Skip to main content

Advertisement

Table 4 Percentage of patients with adverse effects in real-world studies

From: Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

Adverse effect Matrana [28]* US cohort [33]* SPAZO [25]**
Fatigue 44% 56% 7.7%
ASTa/ALTb 35%   3.9%/7.8%
Diarrhea 30% 52% 3.6%
Hypothyroidism 18%   
Nausea/vomiting 17% 40%/44% −/1.1%
Arterial hypertension 27% 4%
Anemia    2.6%
Dropout rate 12%   11.9%
  1. aAST aspartate aminotransferase; bALT alanine aminotransferase
  2. *All grades adverse events according to CTCAE; **Only grade 3–4 adverse effects were reported